Glowface's website sells unapproved, misbranded injectable Botulax botulinum toxin drugs to U.S. consumers, FDA says.
What happened
FDA reviewed the website www.glowface.store and found that it offers unapproved and misbranded injectable botulinum toxin drug products for sale to U.S. consumers. The letter cites Botulax 200U set and Botulax 200U as examples, noting the website claim that the product is used for facial wrinkles, muscle spasm, hyperhidrosis, and blepharospasm. FDA says there are no approved applications for these products and their labeling lacks adequate directions for use.
What FDA found
The website offers botulinum toxin drug products that are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act § 505(a) and § 301(d) [21 U.S.C. §§ 355(a), 331(d)]The products are prescription drugs, but their labeling does not bear adequate directions for use by a layperson.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]By offering the drugs for sale to U.S. consumers, the website causes misbranded drugs to be introduced into interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA requests that www.glowface.store stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must notify FDA in writing within 15 working days describing corrective steps and how it will prevent recurrence, or explain why it cannot complete corrections in that time.
Who should pay attention
- online sellers of injectable cosmetic drugs
- med spas and clinics that buy botulinum toxin products
- consumers buying Botox-like products online
This is a summary. Read the original letter on fda.gov.